Sipuleucel-T (APC8015) for prostate cancer. Expert Rev. Anticancer Ther. 6:1163-1167.So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006; 6: 1163-1167.R. So-Rosillo and E. J. Small, "Sipuleucel-T (APC8015) for prostate cancer," ...
When prostate cancer no longer responds to androgen deprivation therapy (also known as ADT or hormone therapy) and spreads to other parts of the body, it is known as mCRPC. This means that the cancer cells have become resistant to the effects of ADT and may spread to other parts of the ...
Prostate cancer is described as advanced when it has progressed despite treatment to lower testosterone. When the cancer no longer responds to treatment like this, it can also be described as castration-resistant prostate cancer (CRPC). When CRPC has spread to other parts of the body, it’s...
大部分晚期前列腺癌患者都会发展为转移性去势性抵抗前列腺癌( metastatic castration- resistant prostate cancer,mCRPC).而mCRPC一直是临床的治疗难点,因其恶性程度高,生存较差,也缺少有效的治疗手段。 2010 年 4 月,Sipuleucel-T 作为首个新型肿瘤免疫治疗药物获得了 FDA 的批准,为mCRPC患者带来了一线曙光。 图片来自...
What is metastatic castration-resistant prostate cancer? Metastatic castration-resistant prostate cancer (mCRPC) is a form of advanced prostate cancer.
前列腺癌(prostate-cancer)治疗目前涉及靶向药和免疫治疗方法: 1、奥拉帕尼(Olaparib、奥拉帕尼),是多聚二磷酸腺苷核糖聚合酶(PARP)抑制剂,用于治疗BRCA基因突变的肿瘤, 比如卵巢癌,乳腺癌,前列腺癌。临床研究显示:奥拉帕尼无论是作为单药治疗或联合铂类为基础的化疗,均能够抑制试管中肿瘤细胞的生长,和减少人类肿瘤的生...
Prostate cancer immunotherapy with sipuleucel-T:current standards and future directions. WEI X X,FONG L,SMALL E J. Expert Review of Vaccines . 2015Wei, X.X.; Fong, L.; Small, E.J. Prostate cancer immunotherapy with sipuleucel-t: Current standards and future directions. Expert Rev. Vaccines...
When prostate cancer no longer responds to androgen deprivation therapy (also known as ADT or hormone therapy) and spreads to other parts of the body, it is known as mCRPC. This means that the cancer cells have become resistant to the effects of ADT and may spread to other parts of the ...
PROVENGE has no contraindications, and does not preclude other treatments for prostate cancer. Common side effects of Immunotherapy The most common side effects of PROVENGE are generally mild to moderate and are well tolerated. Most infusion-related side effects are resolved within 1 or 2 days. ...
另外,中国前列腺癌患者5年总生存率也远低于北美,中国的5年生存率为69.2%,北美为97.4%。大部分晚期前列腺癌患者都会发展为转移性去势性抵抗前列腺癌( metastatic castration- resistant prostate cancer,mCRPC).而mCRPC一直是临床的治疗难点,因其恶性程度高,生存较差,也缺少有效的治疗手段。